The Institute for Asthma and Allergy has been a leading center for the study and treatment of urticaria and angioedema for over 20 years. Our clinic was a site for the early clinical trials leading to the approval of the first prophylactic therapy for patients with hereditary angioedema (HAE), Cinryze, the first acute therapy for HAE, Kallibitor, and the only currently approved therapy for chronic spontaneous urticaria (CSU), Xolair. Since those initial trials, The Institute for Asthma and Allergy has been involved in essentially every phase 2 and 3 HAE and CSU trial leading to the approval 9 different therapies for these difficult to treat conditions. At this time, we are actively recruiting patients for multiple angioedema and urticaria studies (see links below).
Our clinic has over 700 new patient visits per year for the evaluation of urticaria and/or angioedema. Our physicians have access to the latest tests to accurately make diagnosis, screen for co-morbidities, and offer appropriate treatments. Additionally, we pride ourselves in patient education, so that patients and their families understand these complex and at times frustrating conditions. We also have been involved in physician education with a number of our physicians lecturing nationally and internationally on these disease states.
Patient Education links
United States Hereditary Angioedema Association
ACARE angioedema network:
UCARE urticaria network:
Active Clinical Trials
Please contact our clinical trials unit at 301-986-0670.
Phase 3 oral therapy for chronic spontaneous urticaria:
Phase 2 therapy for chronic spontaneous urticaria:
Phase 2 therapy for chronic inducible (cold or dermatographic) urticaria:
Phase 3 oral acute therapy for HAE (Kalvista)
Phase 3 oral acute therapy for HAE (Pharvaris)
Long-acting prophylactic for HAE
Gene therapy for HAE
Gene editing for HAE